Literature DB >> 205724

Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis.

J W Prineas, R G Wright.   

Abstract

Perivascular cells in CNS tissue from six multiple sclerosis (MS) patients and a patient with motor neuron disease were examined by light and electron microscopy. Lymph node tissue from one MS patient was also examined. CNS perivascular macrophages in both MA and motor neuron disease were found to closely resemble free macrophages elsewhere in the body except that they often contained unusually large primary lysosomes. Cytoplasmic inclusions consisting of membrane-bound stacks of curved linear profiles, presumed to be a product of myelin degradation, were constantly observed in microglia in MS plaques but were rarely observed in perivascular macrophages in the same area. Unidentified cylindrical bodies were observed within cysternae of rough endoplasmic reticulum in some lymph node cells. Quantitative studies of the perivascular cell population in one MS case revealed, in histologically normal white matter 260 lymphocytes and 178 plasma cells per cubic millimeter of fresh tissue. Typical chronic plaque tissue without obvious inflammatory cell cuffing contained 1772 plasma cells per cubic millimeter of fresh tissue. No plasma cells were observed in the CNS in motor neuron disease. The results of this study suggest that perivascular macrophages in the CNS represent a specialized population of monocyte-derived free macrophages, that these cells differ functionally from microglial cells, and that the digestion of myelin breakdown products in MS requires the participation of both cell types. The results also suggest that in some chronic MS cases there is a large, permanent population of CNS plasma cells that persists, like the elevated cerebrospinal fluid IgG level in this disease, for the life of the patient, that these cells, rather than inflammatory cells in fresh lesions, are the major source of this raised IgG, and that the existence of such a population of cells may indicate the continuing expression of antigens in chronic MS lesions in the absence of fresh lesion formation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205724

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  98 in total

1.  Chronic remitting experimental allergic encephalomyelitis in Lewis rats as a model of multiple sclerosis.

Authors:  E Zapryanova; D Deleva; M Bakalska; N Filchev
Journal:  Neurosci Behav Physiol       Date:  1999 Jan-Feb

2.  Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Authors:  R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

Review 3.  Interactions of mast cells with the nervous system--recent advances.

Authors:  D Johnson; W Krenger
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

Review 4.  Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.

Authors:  Mohammed A Omair; Khalid A Alnaqbi; Peter Lee
Journal:  Clin Rheumatol       Date:  2012-05-27       Impact factor: 2.980

Review 5.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

6.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 7.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 8.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Imaging Ca2+ changes in individual oligodendrocytes attacked by T-cell perforin.

Authors:  J Jones; S Frith; S Piddlesden; B P Morgan; D A Compston; A K Campbell; M B Hallett
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

10.  Early events in canine distemper demyelinating encephalomyelitis.

Authors:  B A Summers; H A Greisen; M J Appel
Journal:  Acta Neuropathol       Date:  1979-04-12       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.